Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:2294:59-77.
doi: 10.1007/978-1-0716-1350-4_5.

Preparation and Culture of Organotypic Hippocampal Slices for the Analysis of Brain Metastasis and Primary Brain Tumor Growth

Ellina Schulz  1 , Tim Hohmann  2 , Urszula Hohmann  2 , Ralf-Ingo Ernestus  1 , Mario Löhr  1 , Faramarz Dehghani #  2 , Carsten Hagemann #  3
Affiliations

Preparation and Culture of Organotypic Hippocampal Slices for the Analysis of Brain Metastasis and Primary Brain Tumor Growth

Ellina Schulz et al. Methods Mol Biol. 2021.

Abstract

Brain metastasis is a major challenge for therapy and defines the end stage of tumor progression with a very limited patients' prognosis. Experimental setups that faithfully mimic these processes are necessary to understand the mechanism of brain metastasis and to develop new improved therapeutic strategies. Here, we describe an in vitro model, which closely resembles the in vivo situation. Organotypic hippocampal brain slice cultures (OHSCs) prepared from 3- to 8-day-old mice are well suited for neuro-oncology research including brain metastasis. The original morphology is preserved in OHSCs even after culture periods of several days to weeks. Tumor cells or cells of metastatic origin can be seeded onto OHSCs to evaluate micro-tumor formation, tumor cell invasion, or treatment response. We describe preparation and culture of OHSCs including the seeding of tumor cells. Finally, we show examples of how to treat the OHSCs for life-dead or immunohistochemical staining.

Keywords: Brain tumor; Cryosection; Glioblastoma; Glioma; Immunohistochemistry; Invasion; Life–dead staining; Metastasis; Organotypic hippocampal slice cultures (OHSCs).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Weidle UH, Birzele F, Kollmorgen G et al (2016) Dissection of the process of brain metastasis reveals targets and mechanisms for molecular-based intervention. Cancer Genomics Proteomics 13(4):245–258 - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101 - DOI - PubMed
    1. Mayer IA, Abramson VG, Isakoff SJ et al (2014) Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202–1209. https://doi.org/10.1200/JCO.2013.54.0518 - DOI - PubMed - PMC
    1. Elion DL, Jacobson ME, Hicks DJ et al (2018) Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res 78(21):6183–6195. https://doi.org/10.1158/0008-5472.CAN-18-0730 - DOI - PubMed
    1. Ekici K, Temelli O, Dikilitas M et al (2016) Survival and prognostic factors in patients with brain metastasis: single center experience. J BUON 21(4):958–963 - PubMed

LinkOut - more resources